Economic analyses of bone marrow and blood stem cell transplantation for leukemias and lymphoma: What do we know?

T. M. Waters; C. L. Bennett; T. S. Pajeau; K. A. Sobocinski; J. P. Klein; P. A. Rowlings; M. M. Horowitz

doi:10.1038/sj.bmt.1701160

Economic analyses of bone marrow and blood stem cell transplantation for leukemias and lymphoma: What do we know?

T. M. Waters, C. L. Bennett, T. S. Pajeau, K. A. Sobocinski, J. P. Klein, P. A. Rowlings, M. M. Horowitz

Research output: Contribution to journal › Article › peer-review

43 Citations (SciVal)

Abstract

The use of blood and/or bone marrow stem cell transplantation (SCT) grew extensively in the last decade as technological advances led to improved outcomes and wider availability. The first study of SCT costs, however, was not published until 1989. This paper summarizes current knowledge about costs and cost-effectiveness of allogeneic and autologous SCT for leukemias and lymphoma. Methodological issues in cost studies such as types of costs, methods of data collection, and time horizons are discussed, and studies are evaluated with regard to these issues. Considerations specific to economic analyses of SCT are considered, including the potential impact of technological changes, learning curve effects, and inter-institutional differences.

Original language	English
Pages (from-to)	641-650
Number of pages	10
Journal	Bone Marrow Transplantation
Volume	21
Issue number	7
DOIs	https://doi.org/10.1038/sj.bmt.1701160
State	Published - Apr 1 1998

Bibliographical note

Funding Information:
This work was supported by HRSA 103HR951181P000-0000 and Searle.

Keywords

Cost-effectiveness
Economics
Stem cell transplantation

ASJC Scopus subject areas

Hematology
Transplantation

Access to Document

10.1038/sj.bmt.1701160

Cite this

@article{f632857444804271aa8d03fea17fbf57,

title = "Economic analyses of bone marrow and blood stem cell transplantation for leukemias and lymphoma: What do we know?",

abstract = "The use of blood and/or bone marrow stem cell transplantation (SCT) grew extensively in the last decade as technological advances led to improved outcomes and wider availability. The first study of SCT costs, however, was not published until 1989. This paper summarizes current knowledge about costs and cost-effectiveness of allogeneic and autologous SCT for leukemias and lymphoma. Methodological issues in cost studies such as types of costs, methods of data collection, and time horizons are discussed, and studies are evaluated with regard to these issues. Considerations specific to economic analyses of SCT are considered, including the potential impact of technological changes, learning curve effects, and inter-institutional differences.",

keywords = "Cost-effectiveness, Economics, Stem cell transplantation",

author = "Waters, {T. M.} and Bennett, {C. L.} and Pajeau, {T. S.} and Sobocinski, {K. A.} and Klein, {J. P.} and Rowlings, {P. A.} and Horowitz, {M. M.}",

note = "Funding Information: This work was supported by HRSA 103HR951181P000-0000 and Searle.",

year = "1998",

month = apr,

day = "1",

doi = "10.1038/sj.bmt.1701160",

language = "English",

volume = "21",

pages = "641--650",

number = "7",

}

TY - JOUR

T1 - Economic analyses of bone marrow and blood stem cell transplantation for leukemias and lymphoma

T2 - What do we know?

AU - Waters, T. M.

AU - Bennett, C. L.

AU - Pajeau, T. S.

AU - Sobocinski, K. A.

AU - Klein, J. P.

AU - Rowlings, P. A.

AU - Horowitz, M. M.

N1 - Funding Information: This work was supported by HRSA 103HR951181P000-0000 and Searle.

PY - 1998/4/1

Y1 - 1998/4/1

N2 - The use of blood and/or bone marrow stem cell transplantation (SCT) grew extensively in the last decade as technological advances led to improved outcomes and wider availability. The first study of SCT costs, however, was not published until 1989. This paper summarizes current knowledge about costs and cost-effectiveness of allogeneic and autologous SCT for leukemias and lymphoma. Methodological issues in cost studies such as types of costs, methods of data collection, and time horizons are discussed, and studies are evaluated with regard to these issues. Considerations specific to economic analyses of SCT are considered, including the potential impact of technological changes, learning curve effects, and inter-institutional differences.

AB - The use of blood and/or bone marrow stem cell transplantation (SCT) grew extensively in the last decade as technological advances led to improved outcomes and wider availability. The first study of SCT costs, however, was not published until 1989. This paper summarizes current knowledge about costs and cost-effectiveness of allogeneic and autologous SCT for leukemias and lymphoma. Methodological issues in cost studies such as types of costs, methods of data collection, and time horizons are discussed, and studies are evaluated with regard to these issues. Considerations specific to economic analyses of SCT are considered, including the potential impact of technological changes, learning curve effects, and inter-institutional differences.

KW - Cost-effectiveness

KW - Economics

KW - Stem cell transplantation

UR - http://www.scopus.com/inward/record.url?scp=0031895116&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031895116&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1701160

DO - 10.1038/sj.bmt.1701160

M3 - Article

C2 - 9578302

AN - SCOPUS:0031895116

VL - 21

SP - 641

EP - 650

IS - 7

ER -

Economic analyses of bone marrow and blood stem cell transplantation for leukemias and lymphoma: What do we know?

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this